Study to Test the Efficacy and Safety of Drug Eluting vs. Bare-Metal Stents for Saphenous Vein Graft Interventions (BASKET-SAVAGE)
BAsel Stent Kosten Effektivitäts Trial - SAphenous Venous Graft Angioplasty Using Glycoprotein IIb/IIIa Receptor Inhibitors and Drug-Eluting Stents
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Copenhagen, Denmark
- Rigshospitalet
-
Hellerup, Denmark
- Gentofte Hospital
-
-
-
-
-
Leipzig, Germany
- University of Leipzig/Heart Center
-
-
-
-
-
Basel, Switzerland
- University Hospital Basel
-
Zurich, Switzerland
- Triemli Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients undergoing SVG PCI with a target vessel reference diameter ≤ 5.5 mm (visual estimate)
- Documented silent ischemia, stable angina pectoris Canadian Cardiovascular Society (CCS) class I to IV, or acute coronary syndrome
Exclusion Criteria:
- Previous stent implantation anywhere in the target SVG
- Concomitant native vessel PCI
- SVG age <6 months
- Arterial grafts
- Oral anticoagulation
- Platelet count <100x109/L or >700x109/L, white blood cell count <3000 cells/mm3
- Any major non-cardiac condition with a life expectancy <12 months
- Planned elective surgery in the next 12 months
- Known allergies against the components tested
- Enrolled in other study
- No consent
- Patients unlikely to comply to the study treatment and the follow-up visits
- Age <18 years
- Known pregnancy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: 1
Percutaneous coronary intervention
|
Implantation of stent
Other Names:
|
|
Placebo Comparator: 2
Percutaneous coronary intervention
|
Implantation of stent
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
MACE (composite of cardiac death, i.e., all deaths not clearly non-cardiac, non-fatal myocardial infarction, and TVR
Time Frame: 12 months
|
12 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Non-fatal MI and cardiac death; MACE; QoL; individual components of the primary endpoint; non-cardiac death; major bleeding; minor bleeding
Time Frame: 30 days and 6, 12, 36, and 60 months
|
30 days and 6, 12, 36, and 60 months
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Matthias Pfisterer, MD, University Hospital, Basel, Switzerland
- Principal Investigator: Raban Jeger, MD, University Hospital, Basel, Switzerland
- Principal Investigator: Sven Möbius-Winkler, MD, University of Leipzig/Heart Center, Germany
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- BASKET-SAVAGE EKBB# 278/07
- SNF 3200B0_120029 (Other Grant/Funding Number: Schweizer Nationalfond)
- EKBB 278/07 (Other Identifier: Ethics Committee)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.